StockData
Adaptive Biotechnologies Corp logo

Adaptive Biotechnologies Corp (ADPT) stock

ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30
$27.87−1.17 (-4.03%)

Close on Nov 16, 2026Market cap $4.45BP/E –Yield –

Adaptive Biotechnologies total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Adaptive Biotechnologies's total debt was $0 at Jun 30, 2026. For fiscal 2025 it was $131.21M, down 1.6% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$131.21M-1.6%
FY2024Dec 31, 2024$133.28M+2.0%
FY2023Dec 31, 2023$130.66M+4.2%
FY2022Dec 31, 2022$125.36M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0-100.0%
Q1 FY2026Mar 31, 2026$130.55M-2.3%
Q4 FY2025Dec 31, 2025$131.21M-1.6%
Q3 FY2025Sep 30, 2025$131.84M-0.6%
Q2 FY2025Jun 30, 2025$133.57M+1.1%
Q1 FY2025Mar 31, 2025$133.56M+1.5%
Q4 FY2024Dec 31, 2024$133.28M+2.0%
Q3 FY2024Sep 30, 2024$132.70M+2.1%
Q2 FY2024Jun 30, 2024$132.08M+5.4%
Q1 FY2024Mar 31, 2024$131.55M–
Q4 FY2023Dec 31, 2023$130.66M–
Q3 FY2023Sep 30, 2023$129.92M–
Q4 FY2022Dec 31, 2022$125.36M–

More Adaptive Biotechnologies figures

See a number that looks wrong?